HER Family Receptor Abnormalities in Lung Cancer Brain Metastases and Corresponding Primary Tumors

Purpose: To compare the characteristics of deregulation of HER receptors and their ligands between primary tumor and corresponding brain metastases of non–small cell lung carcinoma (NSCLC). Experimental Design: Fifty-five NSCLC primary tumors and corresponding brain metastases specimens were examined for the immunohistochemical expression of epidermal growth factor receptor (EGFR), phosphorylated EGFR, Her2, Her3, and phosphorylated Her3, and their ligands EGF, transforming growth factor-α, amphiregulin, epiregulin, betacellulin, heparin-binding EGFR-like growth factor, neuregulin (NRG) 1, and NRG2. Analysis of EGFR copy number using fluorescence in situ hybridization and mutation by PCR-based sequencing was also done. Results: Metastases showed significantly higher immunohistochemical expression of EGF (membrane: brain metastases 66.0 versus primary tumors 48.5; P = 0.027; nucleus: brain metastases 92.2 versus 67.4; P = 0.008), amphiregulin (nucleus: brain metastases 53.7 versus primary tumors 33.7; P = 0.019), phosphorylated EGFR (membrane: brain metastases 161.5 versus primary tumors 76.0; P < 0.0001; cytoplasm: brain metastases 101.5 versus primary tumors 55.9; P = 0.014), and phosphorylated Her3 (membrane: brain metastases 25.0 versus primary tumors 3.7; P = 0.001) than primary tumors did. Primary tumors showed significantly higher expression of cytoplasmic transforming growth factor-α(primary tumors 149.8 versus brain metastases 111.3; P = 0.008) and NRG1 (primary tumors 158.5 versus brain metastases 122.8; P = 0.006). In adenocarcinomas, a similar high frequency of EGFR copy number gain (high polysomy and amplification) was detected in primary (65%) and brain metastasis (63%) sites. However, adenocarcinoma metastases (30%) showed higher frequency of EGFR amplification than corresponding primary tumors (10%). Patients whose primary tumors showed EGFR amplification tended to develop brain metastases at an earlier time point. Conclusions: Our findings suggest that NSCLC brain metastases have some significant differences in HER family receptor–related abnormalities from primary lung tumors.

[1]  F. Hirsch,et al.  Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group Study. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  L. Sequist,et al.  EGFR tyrosine kinase inhibitors in lung cancer: an evolving story. , 2008, Annual review of medicine.

[3]  P. Wen,et al.  Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinib. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  Jürgen Debus,et al.  Treatment of brain metastases from non-small-cell lung cancer (NSCLC): radiotherapy. , 2004, Lung cancer.

[5]  Ian G. Mills,et al.  The developing role of receptors and adaptors , 2006, Nature Reviews Cancer.

[6]  R. Rodríguez-Barrueco,et al.  Neuregulins and Cancer , 2008, Clinical Cancer Research.

[7]  R. Price,et al.  High expression of ErbB family members and their ligands in lung adenocarcinomas that are sensitive to inhibition of epidermal growth factor receptor. , 2005, Cancer research.

[8]  C. Mountain,et al.  Revisions in the International System for Staging Lung Cancer. , 1997, Chest.

[9]  N. Normanno,et al.  The role of the EGFR signaling in tumor microenvironment , 2008, Journal of cellular physiology.

[10]  Radiotherapy , 1974 .

[11]  Elisabeth Brambilla,et al.  Pathology and genetics of tumours of the lung , pleura, thymus and heart , 2004 .

[12]  J. Krolewski.  Cytokine and growth factor receptors in the nucleus: What's up with that? , 2005, Journal of cellular biochemistry.

[13]  J. Schlessinger,et al.  Nuclear Signaling by Receptor Tyrosine Kinases: The First Robin of Spring , 2006, Cell.

[14]  R. Herbst,et al.  Targeting the epidermal growth factor receptor in non-small cell lung cancer. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[15]  Y. Miller,et al.  Analysis of c-ErbB1/Epidermal Growth Factor Receptor and c-ErbB2/HER-2 Expression in Bronchial Dysplasia: Evaluation of Potential Targets for Chemoprevention of Lung Cancer , 2006, Clinical Cancer Research.

[16]  G. Tortora,et al.  EGFR antagonists in cancer treatment. , 2008, The New England journal of medicine.

[17]  Chan Zeng,et al.  Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  F. Hirsch,et al.  Biological Markers for Non–Small Cell Lung Cancer Patient Selection for Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy , 2006, Clinical Cancer Research.

[19]  M. Varella‐Garcia,et al.  Stratification of non-small cell lung cancer patients for therapy with epidermal growth factor receptor inhibitors: the EGFR fluorescence in situ hybridization assay , 2006, Diagnostic pathology.

[20]  M. Kris,et al.  High incidence of disease recurrence in the brain and leptomeninges in patients with nonsmall cell lung carcinoma after response to gefitinib , 2005, Cancer.

[21]  I. Wistuba,et al.  Epidermal Growth Factor Receptor Abnormalities in the Pathogenesis and Progression of Lung Adenocarcinomas , 2008, Cancer Prevention Research.

[22]  Roy S Herbst,et al.  KRAS Mutation Is an Important Predictor of Resistance to Therapy with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small-Cell Lung Cancer , 2007, Clinical Cancer Research.

[23]  G. Scagliotti,et al.  Epidermal growth factor ligand/receptor loop and downstream signaling activation pattern in completely resected nonsmall cell lung cancer , 2007, Cancer.

[24]  E. Dmitrovsky,et al.  Overexpression of the epidermal growth factor receptor and its ligand transforming growth factor alpha is frequent in resectable non-small cell lung cancer but does not predict tumor progression. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[25]  I. Fidler,et al.  The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited , 2003, Nature Reviews Cancer.

[26]  D. Jans,et al.  Trafficking and signaling pathways of nuclear localizing protein ligands and their receptors , 2004, BioEssays : news and reviews in molecular, cellular and developmental biology.

[27]  J. Yokota,et al.  Frequent EGFR mutations in brain metastases of lung adenocarcinoma , 2006, International journal of cancer.

[28]  Elisa Rossi,et al.  Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. , 2005, Journal of the National Cancer Institute.

[29]  F. Cappuzzo,et al.  Epidermal growth factor receptor targeted therapy by ZD 1839 (Iressa) in patients with brain metastases from non-small cell lung cancer (NSCLC). , 2003, Lung cancer.

[30]  R. Herbst,et al.  Expression of epidermal growth factor (EGF)/transforming growth factor-α by human lung cancer cells determines their response to EGF receptor tyrosine kinase inhibition in the lungs of mice , 2007, Molecular Cancer Therapeutics.

[31]  M. Spitz,et al.  Clinicopathologic Characteristics of the EGFR Gene Mutation in Non–small Cell Lung Cancer , 2006, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[32]  A. Hamburger,et al.  Production of epidermal growth factor related ligands in tumorigenic and benign human lung epithelial cells. , 1999, Cancer letters.

[33]  Roy S Herbst,et al.  Review of epidermal growth factor receptor biology. , 2004, International journal of radiation oncology, biology, physics.

[34]  J. Lester,et al.  Prophylactic cranial irradiation for preventing brain metastases in patients undergoing radical treatment for non-small-cell lung cancer: a Cochrane Review. , 2005, International journal of radiation oncology, biology, physics.

[35]  Cathleen Brdlik,et al.  A pan-HER approach for cancer therapy: background, current status and future development. , 2009, Expert opinion on biological therapy.

[36]  Jie Zhang,et al.  Intratumoral Epiregulin Is a Marker of Advanced Disease in Non–Small Cell Lung Cancer Patients and Confers Invasive Properties on EGFR-Mutant Cells , 2008, Cancer Prevention Research.

[37]  Y. Yatabe,et al.  Epidermal growth factor receptor gene amplification is acquired in association with tumor progression of EGFR-mutated lung cancer. , 2008, Cancer research.

[38]  J. Minna,et al.  Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. , 2006, Journal of the National Cancer Institute.

[39]  J. Kern,et al.  Autocrine activation of ErbB2/ErbB3 receptor complex by NRG-1 in non-small cell lung cancer cell lines. , 2004, Lung cancer.

[40]  H. Stünzi,et al.  Tumours of the lung. , 1974, Bulletin of the World Health Organization.

[41]  Zhong Wen-zhao,et al.  Erlotinib in Lung Cancer - Molecular and Clinical Predictors of Outcome , 2006 .

[42]  T. Kijima,et al.  Gefitinib in patients with brain metastases from non-small-cell lung cancer: review of 15 clinical cases. , 2004, Clinical lung cancer.

[43]  Rick Chappell,et al.  Primary tumor volume of nasopharyngeal carcinoma: prognostic significance for local control. , 2004, International journal of radiation oncology, biology, physics.

[44]  J. Montero,et al.  Neuregulin expression modulates clinical response to trastuzumab in patients with metastatic breast cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  V. Budach,et al.  Prophylactic cranial irradiation in locally advanced non-small-cell lung cancer after multimodality treatment: long-term follow-up and investigations of late neuropsychologic effects. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[46]  Yusuke Nakamura,et al.  Prediction of sensitivity of advanced non-small cell lung cancers to gefitinib (Iressa, ZD1839). , 2004, Human molecular genetics.

[47]  P. Jänne,et al.  High risk of brain metastases in surgically staged IIIA non-small-cell lung cancer patients treated with surgery, chemotherapy, and radiation. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[48]  M. Socinski,et al.  Novel Agents in the Treatment of Lung Cancer: Fourth Cambridge Conference , 2007, Clinical Cancer Research.

[49]  G. Carpenter.  Nuclear localization and possible functions of receptor tyrosine kinases. , 2003, Current opinion in cell biology.

[50]  P. Jänne,et al.  Autocrine Production of Amphiregulin Predicts Sensitivity to Both Gefitinib and Cetuximab in EGFR Wild-type Cancers , 2008, Clinical Cancer Research.

[51]  D. Larson,et al.  Risk of cerebral metastases and neurological death after pathological complete response to neoadjuvant therapy for locally advanced nonsmall‐cell lung cancer , 2007, Cancer.

[52]  P. Mires.  Lines , 2006 .

[53]  J. Minna,et al.  EGFR tyrosine kinase domain mutations are detected in histologically normal respiratory epithelium in lung cancer patients. , 2005, Cancer research.

[54]  M. Meyerson,et al.  Chromosomal Deletions and Progression of Premalignant Lesions: Less Is More , 2008, Cancer Prevention Research.

[55]  I. Fidler,et al.  Modification of the primary tumor microenvironment by transforming growth factor alpha-epidermal growth factor receptor signaling promotes metastasis in an orthotopic colon cancer model. , 2008, The American journal of pathology.